IN
Live price temporarily unavailable.
Price history
Insmed (INSM) is a Health Care company in the Russell 1000. Latest news and coverage below.
Insmed revenue & net income history (FY2016–FY2025)
RevenueNet income
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $0 | $0 | $9.84M | $136.5M | $164.4M | $188.5M | $245.4M | $305.2M | $363.7M | $606.4M |
| Growth (year over year) | — | — | — | +1287.6% | +20.5% | +14.6% | +30.2% | +24.4% | +19.2% | +66.7% |
| Gross profit | $0 | $0 | $7.41M | $112.3M | $124.5M | $144.3M | $190.2M | $239.6M | $278.0M | $483.5M |
| Gross margin | — | — | 75.4% | 82.3% | 75.7% | 76.6% | 77.5% | 78.5% | 76.4% | 79.7% |
| Operating income | −$173.4M | −$188.9M | −$307.3M | −$235.2M | −$265.2M | −$375.1M | −$457.3M | −$709.6M | −$878.3M | −$1.25B |
| Operating margin | — | — | −3124.9% | −172.4% | −161.3% | −199.0% | −186.4% | −232.5% | −241.5% | −205.6% |
| Net income | −$176.3M | −$192.6M | −$324.3M | −$254.3M | −$294.1M | −$434.7M | −$481.5M | −$749.6M | −$913.8M | −$1.28B |
| Net margin | — | — | −3297.2% | −186.4% | −178.9% | −230.6% | −196.3% | −245.6% | −251.2% | −210.5% |
| EPS (diluted) | −$2.85 | −$2.89 | −$4.22 | −$3.01 | −$3.01 | −$3.88 | −$3.91 | −$5.34 | −$5.57 | −$6.42 |
| Balance sheet | ||||||||||
| Cash and equivalents | $162.6M | $381.2M | $495.1M | $487.4M | $532.8M | $716.8M | $1.07B | $482.4M | $555.0M | $510.4M |
| Total assets | $238.0M | $462.0M | $604.6M | $742.3M | $796.2M | $1.24B | $1.66B | $1.33B | $2.03B | $2.26B |
| Total liabilities | $83.5M | $101.0M | $396.3M | $480.6M | $520.3M | $833.0M | $1.57B | $1.66B | $1.74B | $1.53B |
| Long-term debt | $54.8M | $55.6M | $316.6M | $335.9M | $356.3M | $566.6M | $1.13B | $1.16B | $1.10B | $541.0M |
| Shareholders' equity | $154.5M | $361.1M | $208.3M | $261.7M | $275.9M | $410.5M | $88.0M | −$331.9M | $285.4M | $739.0M |
| Cash flow | ||||||||||
| Operating cash flow | −$146.7M | −$159.6M | −$258.0M | −$250.6M | −$219.3M | −$363.3M | −$400.4M | −$536.2M | −$683.9M | −$935.0M |
| Capital expenditure | $4.20M | $3.00M | $13.1M | $42.3M | $6.24M | $7.29M | $9.88M | $13.3M | $21.9M | $32.6M |
| Free cash flow | −$150.9M | −$162.6M | −$271.1M | −$292.9M | −$225.6M | −$370.6M | −$410.3M | −$549.5M | −$705.8M | −$967.6M |
RevenueNet income
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $93.4M | $104.4M | $92.8M | $107.4M | $142.3M | $263.8M | $306.0M | $425.5M |
| Growth (year over year) | +18.2% | +24.8% | +22.9% | +18.9% | +52.4% | +152.6% | +229.6% | +296.1% |
| Gross profit | $72.3M | $78.3M | $71.5M | $79.3M | $113.0M | $219.6M | $258.5M | $358.3M |
| Gross margin | 77.3% | 75.0% | 77.1% | 73.9% | 79.4% | 83.2% | 84.5% | 84.2% |
| Operating income | −$213.4M | −$230.4M | −$248.1M | −$312.9M | −$366.0M | −$319.7M | −$153.3M | −$1.55M |
| Operating margin | −228.4% | −220.6% | −267.3% | −291.3% | −257.1% | −121.2% | −50.1% | −0.4% |
| Net income | −$220.5M | −$235.5M | −$256.6M | −$321.7M | −$370.0M | −$328.5M | −$163.6M | −$13.2M |
| Net margin | −236.0% | −225.5% | −276.4% | −299.5% | −260.0% | −124.5% | −53.5% | −3.1% |
| EPS (diluted) | −$1.27 | −$1.30 | −$1.42 | −$1.70 | −$1.75 | −$1.55 | −$0.76 | −$0.06 |
| Balance sheet | ||||||||
| Cash and equivalents | $461.5M | $555.0M | $403.2M | $1.28B | $334.8M | $510.4M | $582.2M | $544.8M |
| Total assets | $2.05B | $2.03B | $1.80B | $2.48B | $2.36B | $2.26B | $2.08B | $2.10B |
| Total liabilities | $1.57B | $1.74B | $1.70B | $1.23B | $1.42B | $1.53B | $1.37B | $1.35B |
| Long-term debt | $954.8M | $1.10B | $1.11B | $538.5M | $539.7M | $541.0M | $542.2M | $543.5M |
| Shareholders' equity | $483.4M | $285.4M | $99.2M | $1.25B | $945.6M | $739.0M | $704.9M | $757.5M |
| Cash flow | ||||||||
| Operating cash flow | −$180.9M | −$196.0M | −$262.1M | −$205.6M | −$219.8M | −$247.6M | −$222.7M | −$88.8M |
| Capital expenditure | $3.69M | $6.77M | $10.1M | $3.48M | $2.42M | $16.6M | $3.48M | $6.26M |
| Free cash flow | −$184.6M | −$202.8M | −$272.2M | −$209.1M | −$222.2M | −$264.2M | −$226.2M | −$95.1M |
From Insmed's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Insmed
- Headquarters
- Bridgewater, New Jersey From SEC filings, Oct 2026
Recent News (3)
-
Insmed stock falls as CFO Sara Bonstein to step down
Insmed stock falls as CFO Sara Bonstein to step down
-
Insmed CFO Sara Bonstein to step down on October 30
Insmed CFO Sara Bonstein to step down on October 30
-
Insmed Announces CFO Transition —Sara Bonstein Will Step Down as CFO on October 30 After Nearly Seven Years of Dedicated Leadership— —Company Reaffirms Full-Year 2026 Financial Guidance— —Company Announces Third-Quarter 2026 Financi…
Other Health Care companies to compare with INSM
- INKT MiNK Therapeutics
- INMB Inmune Bio Inc
- INMD InMode
- INNV Innovage Holding Corp
- INSP Inspire Medical Systems
- INTS Intensity Therapeutics
- INVA Innoviva Inc
- IONS Ionis Pharmaceuticals